目的：通过标准临床路径费用结构识别费用异常病组并进行合理控费。方法：以某三甲医院2022年4月-2023年3月进入临床路径的病案首页信息为基础，以医保部门返回的病种分组数据为研究资料，用回顾性分析法识别并研究超支付标准病种的费用结构，运用药品、材料考核进行合理控费。结果：结合控费系统，实现费用异常病组的识别及控费。以药品费用超额较高的病组“HC29胆囊切除手术”及材料费用超额较高的病组“JA29乳房恶性肿瘤根治性切除术”为例，HC29病组次均药品费用和JA29病组次均材料费用均显著降低，并具有统计学意义（P＜0.05）。结论：基于临床路径的合理控费措施是有效的，该举措能够帮助临床科室及管理部门找出费用异常点，通过数据逐级追溯定位到控费责任人，是一项科学有效的合理控费方式。

Objective：To identify the abnormal cost groups through the standard clinical pathway cost structure and control the cost reasonably. Method：Based on the first page information of medical records in a certain grade Ahospital from April，2022 to March，2023，and the grouping data of diseasesreturned by the medical insurance department as the research data，the cost structure of standard diseases with overpayment was identified and studied by retrospective analysis，and the cost was reasonably controlled by combining the means of drug and material assessment. Results：Combined with the cost control system，the identification and cost control of abnormal disease groups were realized.For example，in the case of “Cholecystectomy with HC29” and “Radical Mastectomy with JA29”，the average drug cost per patient in the case of HC29 decreased. The average material cost of JA29 disease group decreased. The above data changes were statistically significant（P＜0.05）. Conclusion：The reasonable cost control measures based on clinical pathway are effective，which can help clinical departments and management departments to find out the abnormal points of cost and locate the person in charge of cost control step by step through data tracing，and it is a scientific and effective way of reasonable cost control.